Question 1

What are the main types of bronchodilators used to treat lower respiratory disorders?

Accepted Answer

Bronchodilators include methylxanthines, β2-adrenoceptor agonists, muscarinic receptor antagonists, and cysteinyl leukotriene receptor antagonists. Each type relaxes airway muscles through different mechanisms to ease breathing. Methylxanthines inhibit phosphodiesterase enzymes, β2-agonists activate specific adrenergic receptors, and muscarinic antagonists block acetylcholine binding. These drugs provide both rescue and maintenance therapy for conditions like asthma and COPD.

Question 2

How do methylxanthines work to improve airflow in the lungs?

Accepted Answer

Methylxanthines inhibit phosphodiesterase enzymes, particularly PDE-4, in airway smooth muscle. This prevents the breakdown of cyclic adenosine monophosphate (cAMP), increasing intracellular cAMP levels. Elevated cAMP activates protein kinase A, which reduces muscle contraction signals, resulting in relaxed bronchial smooth muscles and improved airflow for respiratory relief.

Question 3

What is the role of anti-inflammatory drugs in managing lower respiratory disorders?

Accepted Answer

Anti-inflammatory drugs reduce or prevent inflammation in the lower respiratory tract. Glucocorticoids suppress inflammatory genes or activate anti-inflammatory counterparts, curbing inflammation cascades. Mast cell stabilizers inhibit calcium ion influx into mast cells, preventing release of inflammatory mediators. Immunomodulators, including IgE and interleukin inhibitors, suppress allergic reactions and protect airways from chronic inflammation damage.

Question 4

How do mast cell stabilizers prevent inflammation in asthma?

Accepted Answer

Mast cell stabilizers block calcium ion entry into mast cells, preventing the release of inflammatory mediators that contribute to ongoing inflammation. By inhibiting this calcium influx, these drugs effectively reduce inflammation and help manage asthma symptoms. They are commonly used as antiasthmatic drugs to control the inflammatory response in the lower respiratory tract.

Question 5

What is the difference between short-acting and long-acting bronchodilator therapy?

Accepted Answer

Short-acting bronchodilators, such as short-acting β2-adrenoceptor agonists, provide quick relief during acute bronchoconstriction by rapidly relaxing bronchial muscles and facilitating smoother airflow. Long-acting therapy, including long-acting β2-adrenoceptor agonists, provides maintenance treatment for sustained symptom control. Rescue therapy addresses immediate breathing difficulties, while maintenance therapy prevents symptoms over extended periods.

Question 6

How do muscarinic receptor antagonists improve breathing in lower respiratory disorders?

Accepted Answer

Muscarinic receptor antagonists block acetylcholine from binding to M3 receptors in bronchial muscles, enabling them to relax and fostering improved breathing. By preventing acetylcholine-mediated muscle contraction, these drugs reduce bronchoconstriction and ease airflow. They are used alongside other bronchodilators and anti-inflammatory agents in comprehensive management of asthma and COPD.

Question 7

What role do immunomodulators play in treating allergic inflammation in the respiratory system?

Accepted Answer

Immunomodulators, including IgE and interleukin inhibitors, strategically suppress the immune elements that trigger allergic reactions. They protect the respiratory system from collateral damage caused by chronic inflammation. By targeting specific immune responses to allergic inflammation, immunomodulators complement other anti-inflammatory drugs in managing lower respiratory disorders with an allergic component.

תרופות להפרעות בדרכי הנשימה התחתונות: סקירה כללית

Browse More Videos